- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02806414
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
October 1, 2021 updated by: Tissa Hata, MD, University of California, San Diego
A Single Site Evaluation of the Inhibitory Effects of Topical Ivermectin on Serine Protease Activity and Production of LL-37 Cathelicidin Peptide, Biochemical Markers of Rosacea-specific Inflammation and on the Skin Microbiome in Rosacea.
This study will assess the role of topical Ivermectin 1% cream and its effect on protease and antimicrobial peptide expression and on the skin microbiome (the microorganisms that live on the skin) in rosacea.
This is a single-site 16-week open-label study at University of California, San Diego.
The investigators will do this by first measuring serine protease activity and cathelicidin and skin microbiome of all subjects.
All subjects will receive Ivermectin topical cream and will be instructed on how to apply it daily for 12 weeks.
Participants will return for monthly visits during which their clinical symptoms of facial redness and number of facial papules will be scored, and they will have repeat tape stripping and/or skin swabs.
At the end of the study, tape strips and skin swabs will be analyzed to determine serine protease activity and skin microbiome of participants at each of their visits and expression of cathelicidin (LL-37) mRNA.
The investigators will then look at changes in serine protease activity and LL-37 expression and skin microbiome over time, and they will also determine whether or not these changes correlate with disease severity.
Study Overview
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92122
- UCSD Division of Dermatology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject is male or non-pregnant female, 18 - 70 years of age.
- Subjects willing and able to give informed consent.
- Subjects willing and able to comply with the requirements of the study.
- Subject has the clinical diagnosis of rosacea with at least one inflammatory papule and at least mild erythema.
- Subject has been on a stable dose for greater than 3 months of medications for treatment of concurrent medical condition (including oral contraceptive pills, vasodilators, adrenergic blocking agents) OR the investigator has determined that the medications are unlikely to affect the patient's rosacea and/or treatment during the study
- Subject is in general good health in the opinion of the investigator.
- Subject has normal baseline labs or in the opinion of the investigator are values are not clinically significant and would not inhibit the ability to monitor the patient for both safety and efficacy throughout the study.
Exclusion Criteria:
- Subject has a diagnosis of Steroid Rosacea or Pyoderma Faciale (rosacea fulminans).
- Subject has used facial topical therapies (OTC drug products or prescription products) for any reason within the prior 28 days
- Subject has used systemic corticosteroid or systemic antibiotics (especially doxycycline, minocycline, tetracycline, metronidazole) within the prior 28 days.
- Subject has had laser or light-based treatment for rosacea within the prior 3 months.
- Subject has had systemic retinoids and retinoid derivatives over the past 6 months
- Subject has a known hypersensitivity or allergy to topical ivermectin or components of the vehicle.
- Subject is pregnant or lactating or planning a pregnancy during the duration of the study
- Subject has been treated with another investigational device or drug within 28 days prior to study enrollment or intends to participate in a clinical trial concurrent with this study
- Subject has clinically significant findings, medical history or conditions (other than rosacea), which in the opinion of the Investigator may compromise the study, treatment protocol, or safety of the patient or treatment allocation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ivermectin
All subjects will be treated with topical ivermectin daily for up to 12 weeks.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative Trypsin-like Enzyme Activity
Time Frame: 12 weeks
|
Activity was quantified using a protease activity assay involving aprotinin, a known selective inhibitor of trypsin-related enzyme activity
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative Fold Change in Cathelicidin mRNA
Time Frame: 12 weeks
|
Ratio of fold change in cathelicidin mRNA at 12 weeks to fold change in cathelicidin mRNA at baseline
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Tissa Hata, MD, UCSD Division of Dermatology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2016
Primary Completion (Actual)
July 1, 2019
Study Completion (Actual)
May 1, 2021
Study Registration Dates
First Submitted
June 15, 2016
First Submitted That Met QC Criteria
June 15, 2016
First Posted (Estimate)
June 20, 2016
Study Record Updates
Last Update Posted (Actual)
October 5, 2021
Last Update Submitted That Met QC Criteria
October 1, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UCSD 160765
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rosacea
-
Amorepacific CorporationCompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaKorea, Republic of
-
Actavis Inc.CompletedModerate to Severe Papulopustular RosaceaUnited States
-
University of California, DavisCompletedRosacea | Ocular Rosacea | Cutaneous RosaceaUnited States
-
bioRASI, LLCCompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
Bionou Research, S.L.RecruitingRosacea | Rosacea, Papulopustular | Rosacea Papular TypeSpain
-
Galderma R&DCompleted
-
Cutera Inc.CompletedPapulopustular Rosacea | Erythematotelangiectatic RosaceaUnited States
-
Eye Associates of Central TexasWithdrawn
-
Dermata TherapeuticsActive, not recruiting
-
AiViva BioPharma, Inc.Withdrawn
Clinical Trials on Ivermectin
-
Pierre Fabre DermatologyWithdrawn
-
Zydus Worldwide DMCCCatawba Research, LLCCompletedFacial RosaceaUnited States
-
Taro Pharmaceuticals USACompletedLice; Head LiceUnited States
-
Humanis Saglık Anonim SirketiCompleted
-
Assistance Publique - Hôpitaux de ParisCompletedIvermectin | Gale | Severe Forms of Scabies | Oral Parasitic DrugFrance
-
Mahidol UniversityMinistry of Health, ThailandUnknown
-
Actavis Inc.Teva Pharmaceuticals USACompleted
-
Wake Forest University Health SciencesGalderma R&DActive, not recruiting
-
South Valley UniversityRecruiting